Idelvion (albutrepenonacog alfa) is licensed for the treatment and prophylaxis of bleeding in patients with haemophilia B. It can be given at intervals of up to 2 weeks.
Albutrepenonacog alfa is a fusion protein comprising recombinant coagulation factor IX linked to recombinant albumin to prolong its half-life in the body. The protein remains intact in the circulation until factor IX is activated, whereupon albumin is cleaved off, releasing activated factor IX for coagulation.
The dose and duration of treatment with Idelvion are determined by the severity of factor IX deficiency, the location and extent of bleeding and the patient's age and clinical condition. When used for prophylaxis, usual doses are between 35iu/kg and 50iu/kg once weekly.
Idelvion is administered slowly via intravenous injection, up to a maximum rate of 5ml/min. Factor IX levels should be monitored during treatment to ensure the dose and dosing frequency are appropriate.
Patients may experience injection site reactions and headaches after treatment with albutrepenonacog alfa. Dizziness, rashes, eczema and hypersensitivity reactions have also been reported uncommonly.
The safety and efficacy of albutrepenonacog alfa has not been established in patients who have not been previously treated.